NVDA
NVIDIA
-- 142.620 TSLA
Tesla
-- 406.580 PLTR
Palantir
-- 78.980 AAPL
Apple
-- 222.780 MSTR
MicroStrategy
-- 353.670 
NEWS
Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries
PR Newswire· 9 mins ago7mins
Hoth Therapeutics(HOTH.US)
2.370
+3.94%
The Company affirms that it has no plans for a public or private offering at this time.
Hoth's financial position remains robust, with a strong balance sheet that includes over $10 million in cash and no debt.
Hoth is pleased to report that enrollment in the HT-001 clinical trial is proceeding as planned, with all trial sites now active and enrolling participants.
NEW YORK, Jan. 8, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative, patient-focused treatments, today responded to recent market rumors and inquiries from shareholders regarding its financial plans and ongoing clinical trials.
The Company affirms that it has no plans for a public or private offering at this time. Hoth's financial position remains robust, with a strong balance sheet that includes over $10 million in cash and no debt. This fiscal strength positions the Company well to execute its strategic initiatives and advance its pipeline without the immediate need for additional financing.
"We want to assure our shareholders that Hoth remains focused on creating long-term value and advancing our clinical programs," said Robb Knie, Chief Executive Officer of Hoth Therapeutics. "With our strong financial foundation, we are well-equipped to continue progressing our innovative therapies."
The Company also provided an update on the clinical development of HT-001, its lead therapeutic candidate designed to treat rash and skin disorders associated with cancer therapy. Hoth is pleased to report that enrollment in the HT-001 clinical trial is proceeding as planned, with all trial sites now active and enrolling participants.
"Activating all trial sites for HT-001 marks a significant milestone in the development of this promising therapy," Robb Knie added. "We are excited about the progress and remain committed to addressing unmet needs for patients undergoing cancer treatment."
PR Newswire· 9 mins ago7mins
Hoth Therapeutics(HOTH.US)
2.370
+3.94%
The Company affirms that it has no plans for a public or private offering at this time.
Hoth's financial position remains robust, with a strong balance sheet that includes over $10 million in cash and no debt.
Hoth is pleased to report that enrollment in the HT-001 clinical trial is proceeding as planned, with all trial sites now active and enrolling participants.
NEW YORK, Jan. 8, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative, patient-focused treatments, today responded to recent market rumors and inquiries from shareholders regarding its financial plans and ongoing clinical trials.
The Company affirms that it has no plans for a public or private offering at this time. Hoth's financial position remains robust, with a strong balance sheet that includes over $10 million in cash and no debt. This fiscal strength positions the Company well to execute its strategic initiatives and advance its pipeline without the immediate need for additional financing.
"We want to assure our shareholders that Hoth remains focused on creating long-term value and advancing our clinical programs," said Robb Knie, Chief Executive Officer of Hoth Therapeutics. "With our strong financial foundation, we are well-equipped to continue progressing our innovative therapies."
The Company also provided an update on the clinical development of HT-001, its lead therapeutic candidate designed to treat rash and skin disorders associated with cancer therapy. Hoth is pleased to report that enrollment in the HT-001 clinical trial is proceeding as planned, with all trial sites now active and enrolling participants.
"Activating all trial sites for HT-001 marks a significant milestone in the development of this promising therapy," Robb Knie added. "We are excited about the progress and remain committed to addressing unmet needs for patients undergoing cancer treatment."
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
7058
Followers
46
Following
76K
Visitors
Follow
Discussing
Trump 2.0 Era: What's the next opportunity in the markets?
▪️Could Trump's crypto policies potentially benefit the crypto market? ▪️Might his tariff policies have a positive effect on Chinese stocks
Michael McCarthy CCO
Jan 3 11:57
Ask a strategist - Trump's first day